First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities turns positive
Q1 FY2026 other non-current liabilities was $0, compared with -$391.6M a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026.
- Other non-current liabilities increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 other non-current liabilities of $0 is the 6th highest of the 10 companies compared; the peer median is $353K.
- Its year-over-year change of +100.0% is the 2nd highest of 6, against a peer median of -34.1%.
- Other non-current liabilities amounts to 0.0% of total assets for TRAX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $30.38M | -12.7% | +237.1% | 20.7% | |
| Mar 2026 | $11M | -64.0% | -31.8% | 5.5% | |
| Jun 2026 | $7.23M | +265.0% | +159.9% | 3.0% | |
| Jun 2026 | $678K | — | — | 0.5% | |
| Mar 2026 | $353K | -34.1% | — | 0.1% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | +100.0% | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -3.2% | 0.0% | |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $353K | -34.1% | +78.4% | 0.1% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.